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Abstract
Background: Phyllanthus amarus (Schum & Thonn), a plant belonging to the family of Euphorbiaceae is used in
Ivorian traditional medicine to treat cardiovascular disorders such as hypertension. However, although this plant has
been described as a diuretic agent, the underlying mechanism remains unclear. Therefore, the aim of the present
study was to investigate the mechanism action of diuretic effects of an ethanolic fraction of Phyllanthus amarus
(EFPA) in rats.
Methods: Effects of EFPA on urinary excretion were carried out for doses ranging from 5 to 80 mg/kg given by
intraperitoneal injection (i.p.) and compared with that induced by furosemide (5 mg/kg) after 8 h. Thereafter, the
diuretic activity of EFPA was also evaluated in the presence of indomethacin (5 mg/kg, i.p.) in order to determine
the involvement of prostaglandins, after 24 h.
Results: Between 5 and 80 mg/kg, EFPA induced a significant urinary excretion. The profile of urinary excretion
showed that after 2 h, the highest dose of 80 mg/kg induced a urinary volumetric excretion (UVE), which was
similar to that induced by furosemide. After 24 h, EFPA at 10 mg/kg increased significantly UVE, Na+ (43 mEq) and
Cl¯ (97 mEq) urinary excretions without promoting kaliuresis. In rats pretreated with indomethacin, the urinary
excretion and the natriuretic response of EFPA were significantly reduced.
Conclusion: Altogether, this study has shown that EFPA promotes a significant urinary excretion of water and Na+,
confirming its diuretic activity. Moreover, the increased diuresis could be attributed, at least in part, to the involvement
of prostaglandins.
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Background
The World Health Organization (WHO) encourages de-
veloping countries from the tropical area to develop thera-
peutic alternatives in the management of priority and
emerging diseases such as high blood pressure and
diabetes [1]. This strategy involves exploitation of the po-
tential medicinal plants from the local pharmacopoeia. In
this context, many studies on traditional medicine are
undertaken in African countries against hypertension [2].
In Côte d’Ivoire, several traditional herbal preparations
are used by the local population to treat hypertension,
among them, Phyllanthus amarus (Schum & Thonn), a
plant belonging to the family of Euphorbiaceae [3]. This
plant has various applications in traditional medicine
throughout the world [4, 5]. In the Ayurvedic medicine,
decoctions of the whole plant are used to treat malaria
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[6], and skin disorders [7]. In traditional West African
pharmacopoeia, particularly in Nigeria, the administra-
tion (per os) of decoctions of leaves and seeds extracts
are used to treat diabetes [8].
Pharmacological studies in mice and rats have shown that
Phyllanthus amarus has antiviral [5], hepatoprotective [9,
10] and hypoglycemic activities [11]. A previous study [12]
has suggested that Phyllanthus amarus, described as diur-
etic agent, might be of interest in the treatment of hyper-
tension. The antihypertensive activity of Phyllanthus
amarus has been related to stimulation of muscarinic re-
ceptors leading to the formation of endothelium-derived ni-
tric oxide (NO) and also to blocking of calcium channels
[13, 14]. Moreover, Phyllanthus species have been shown to
have several beneficial effects on the vascular function.
Phyllanthin and hypophyllanthin, two major compounds
from Phyllanthus amarus, decreased vascular tone by
endothelium-independent mechanisms via the blockade of
Ca2+ entry into the vascular smooth muscle and inhibition
of phenylephrine-induced Ca2+ release from the endoplas-
mis reticulum [15]. Phyllanthus acidus also inhibited vascu-
lar tone in aortic rings by acting directly on the smooth
muscle and/or by releasing NO from the endothelium [16].
Moreover, 6 weeks after oral administration of an n-
butanol extract of the leaves of Phyllanthus acidus, a de-
creased contractile response to phenylephrine and an en-
hanced endothelium-dependent relaxation to acetylcholine
were observed in aortic rings of middle-aged male rats [17].
Furthermore, several studies have shown that natural
products such as plant extracts from Hibiscus sabdariffa
and Vepris heterophylla have diuretic properties, which
might contribute to regulate blood pressure [18, 19]. It
is well known that diuretics such as thiazides play a key
role in the management of hypertensive diseases. They
are most often associated with classic antihypertensive
drugs such as angiotensin II type 1 receptor (AT1R)
blockers to optimize blood pressure control. In this case,
the role of diuretics is to potentiate the therapeutic ef-
fect of AT1R blockers by inducing a significant renal
elimination of sodium and water.
The evaluation of the pharmacological effects of a Phyl-
lanthus amarus aqueous extract administered intraven-
ously in normotensive rabbits has shown that at doses
ranging from 4.5 to 71.7 mg/kg, the extract induced a
transient decrease in mean arterial blood pressure of
about 4.8 ± 0.8 to 14.0 ± 0.6 mmHg [14]. The ethanolic
fraction was the most potent fraction inducing about a
11.5 ± 0.5 mmHg reduction of mean arterial blood pres-
sure at 15 mg/kg [14]. In addition, it seemed to be the
most potent extract for diuresis, however the mechanism
action of these diuretic effect remain unclear [20]. The
present study has evaluated the possibility that an ethano-
lic fraction of Phyllanthus amarus has a diuretic effect,
which might contribute to reduce blood pressure.
Methods
Plant material
The whole plant of Phyllanthus amarus (Euphorbiaceae)
was collected in the district of Cocody (Abidjan, Côte
d’Ivoire) in April 2014. This plant has been authenticated
by an expert in Botany (Professor Ake-Assi Laurent) at
the Centre National de Floristique (UFR-Biosciences, Félix
Houphouët-Boigny University, Abidjan, Côte d’Ivoire)
where the voucher specimen was recorded under No. 3,
141 and 248.
Extraction procedure
The ethanolic fraction of Phyllanthus amarus (EFPA)
was prepared as previously described with minor modifi-
cations [14]. Briefly, the whole plant was harvested,
washed, and extracted in boiling distilled water for
30 min at ratio of 500 g of plant for 1 l. The decoction
was filtered and then lyophilized to obtain a powder of
aqueous extract of Phyllanthus amarus (11.72 g from
1 kg of plant). 3 g of lyophilisate were then dissolved in
250 ml of a 70% ethanol solution and suspended into a
separating funnel for 12 h. The upper phase was sepa-
rated and dried using a rotary evaporator (Büchi) to ob-
tain powder of ethanolic fraction of Phyllanthus amarus
(EFPA). Extraction procedure was repeated 5 times and,
the final yield of EFPA preparation was 0.26%.
Pharmacological studies
Animal
Male Wistar rats weighing between 180 and 250 g were
used. Animals were randomly assigned 6 rats per group,
including control, Furosemide (5 mg/kg), EFPA at differ-
ent doses (5, 10, 20, 40 and 80 mg/kg), and EFPA
(10 mg/kg) + indomethacin (5 mg/kg). They were bred
in the animal house of the Ecole Normale Supérieure
(Abidjan). Before starting the experiments, rats were iso-
lated and acclimated for 14 days. They were maintained
under standard laboratory conditions (25 ± 2 °C) with
dark and light cycle (12/12 h) and had free access to a
standard dry pellet diet and water ad libitum. Experi-
ments were performed in accordance to the Guidelines
for experiments involving animals [21, 22].
Evaluation of the diuretic activity
Diuretic activity was determined by the method described
by Kau et al. (1984) with some modifications [23].
In the first step of experiments, the evaluation of the
effects of different doses of the EFPA extracts on urinary
excretion was carried out for doses ranging from 5 to
80 mg/kg body weight i.p. after an 8 h treatment period.
The effect of Phyllanthus amarus extract was compared
with that induced by Furosemide (5 mg/kg, i.p.), used as
a reference loop diuretic drug. The doses evaluated were
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below the maximal tolerated doses of Phyllanthus
amarus administrated i.p. [24].
Thereafter, the diuretic effect of EFPA (10 mg/kg) was
evaluated after 24 h in the presence of indomethacin
(5 mg/kg), a cyclooxygenase inhibitor, in order to evaluate
the role of prostaglandins. Indomethacin was administered
i.p. to rats 1 h prior to the administration of EFPA.
The administration of each test substance was preceded
by fluid overloading with 50 ml/kg of water per os. Rats
were placed individually in metabolic cages. Urine volumes
were collected over either 8 or 24 h periods and were used
to determine the urinary volumetric excretion (U.
VE) from the ratio of the volume of urine excreted
and the volume of fluid overloaded. The urine volumes
expressed as mL/100 g were calculated based on body
weight of rats and urinary volumetric excretion values
are expressed as a percentage of the initial hydric over-
load (50 mL/kg). At the end of the 24 h period, urine
samples were collected and aliquoted into eppendorf
tubes. Animals were anaesthetized by intraperitoneal in-
jections of pentobarbital (50 mg/kg). The thoracic cavity
was opened by surgical operation and blood was taken
directly by heart puncture, put into heparinized tubes
and, thereafter the plasma was obtained by centrifuga-
tion. Finally, animals were sacrificed by exsanguination.
Both urine and plasma aliquots were stored at − 80 °C
for subsequent biochemical analysis.
Analytical procedures
In order to determine the electrolyte content in plasma
and urine samples, several techniques were used. The
determination of sodium (Na+) and potassium (K+) con-
tents was done by photometry, chlorine (Cl−) and urea
concentrations by a colorimetric technique, and the cal-
cium concentration by quantitative CPC method (o-cre-
solphthalein complexone). The creatinine content was
estimated by the kinetics method.
Drugs
Furosemide was from Tocris Bioscience (Abingdon, UK)
and indomethacin from Sigma (Saint Quentin Fallavier,
France).
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis of
data was performed using GraphPad Instat software
(Microsoft, San Diego, California, USA) and Graph Pad
Prism software (Microsoft, San Diego, California, USA).
Statistical analyses were assessed using one-way or two-
way analysis of variance (ANOVA) followed by Bonfer-
roni’s post- test when applicable. Statistical significance
was considered at p < 0.05.
Results
Effect of EFPA on urinary excretion
Intraperitoneal administration of EFPA at doses ranging
from 5 to 80 mg/kg body weight induced significant
urinary excretion in a dose-dependent manner compared
to the control group (p < 0.001; Table 1; Additional file 1:
Figure S1). After 8 h, urinary excretion ranged from 41.2 ±
3.3% to 63.3 ± 3.2%, respectively (Table 1; Additional file 1:
Figure S1). Urinary volumes excreted by the highest dose of
EFPA (80 mg/kg) and 5 mg/kg of Furosemide were time
dependent and significant compared to that of the control
group (p < 0.001; Fig. 1). After 2 h, Furosemide and EFPA
caused similar urinary excretion, whereas at 8 h, the effect
of Furosemide was significantly greater than that of EFPA
(82.2% ± 3.0 versus 63.3 ± 3.2%, respectively at 8 h; Fig. 1).
Effect of indomethacin on EFPA-induced diuresis and
excretion of electrolytes
After 24 h, EFPA at the dose of 10 mg/kg increased sig-
nificantly the urinary volumetric excretion (58.1 ± 2.15%;
p < 0.05; Fig. 2), compared with that of the control group
(16.8 ± 2.29%; p < 0.05; Fig. 2). In presence of indometh-
acin, the urinary volumetric excretion of EFPA was sig-
nificantly reduced, amounted to 33.1 ± 3.5% (p < 0.05;
Fig. 2), however, it remained greater than that of the
control group (p < 0.05; Fig. 2).
After 24 h, EFPA (10 mg/kg) induced a significant
urinary excretion of sodium (90.0 ± 4.7 mEq/L) com-
pared to that of the control group (70.50 ± 6.1 mEq/L;
Table 2; Additional file 2: Figure S2). In rats pretreated
with indomethacin (5 mg/kg), EFPA-induced natriuresis
was significantly reduced to about 43.5 ± 4.4 mEq/L (p <
0.05; Table 2; Additional file 2: Figure S2). In addition to
sodium excretion, EFPA induced also a significant urin-
ary excretion of Cl− from 81.2 ± 3.1 mEq/L to 97.3 ±
2.9 mEq/L, which however was not affected by indo-
methacin (96.7 ± 4.1 mEq/L; Table 2; Additional file 2:
Figure S2). EAPA also caused a significant reduction in
the urinary excretion of K+ compared with that of the
control group (52.2 ± 2.0 mEq/L versus 36.7 ± 1.6 mEq/
L, respectively in the control and EFPA group), but in
the presence of indomethacin, excretion of K+ was in-
creased (61.0 ± 2.4 mEq/L; Table 2; Additional file 2:
Figure S2). The EFPA treatment did not significantly
affect calciury in rats (1.8 ± 0.1 versus 1.7 ± 0.1 mEq/L in
the control and EFPA group, respectively), also in
presence of indomethacin (3.1 ± 0.2 mEq/L; Table 2;
Additional file 2: Figure S2).
Effect of EFPA on plasma electrolyte levels
Control group and rats treated with EFPA (10 mg/kg for
24 h) had similar natremia (114.7 ± 5.5 and 125.5 ±
4.0 mEq/L, respectively; Table 3; Additional file 3: Figure
S3), this effect was not affected in presence of indomethacin
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(119.3 ± 4.4 mEq/L; Table 3; Additional file 3: Figure S3).
The plasma chlorine level observed in rats following the
EFPA treatment was 102.0 ± 4.3 mEq/L, similar to that ob-
served in the control group (104.3 ± 3.9 mEq/L), and not af-
fected by indomethacin (103.3 ± 3.4 mEq/L; Table 3;
Additional file 3: Figure S3). The potassium level was sig-
nificantly reduced after EFPA treatment (70.5 ± 2.9 versus
54.7 ± 2.8 mEq/L; respectively in the control and EFPA
group), this effect was not affected by indomethacin
(Table 3; Additional file 3: Figure S3). The plasma calcium
level following EFPA treatment was similar to that of the
control group (5.2 ± 2.6 mEq/L and 5.4 ± 2.5 mEq/L, re-
spectively) and this response was not affected by indometh-
acin (5.1 ± 2.5 mEq/L; Table 3; Additional file 3: Figure S3).
Effect of EFPA on renal function
After 24 h, the EFPA treatment (10 mg/kg for 24 h)
affected slightly but not significantly the plasma concen-
tration of urea and creatinine in rats, both responses
where significantly increased in presence of indometh-
acin (Table 4).
Discussion
The present findings indicate that an ethanolic fraction of
Phyllanthus amarus (EFPA) at doses ranging from 5 to
80 mg/kg, significantly induced diuresis during an 8 h
period. The profile of urinary excretion showed that after
2 h, at a dose of 80 mg/kg, EFPA induced approximately
the same UVE than that of 5 mg/kg of Furosemide. How-
ever, after 8 h, the urinary excretion of Furosemide was
greater (82%) than that induced by the EFPA (63%). Thus,
these observations indicate that the diuretic effect of EFPA
is relatively strong and sustained [25], as indicated by
about 58% diuretic effect of EFPA at 10 mg/kg after 24 h.
The effect of diuretic substances is commonly associ-
ated with the urinary excretion of electrolytes. The
Table 1 Urinary excretion induced by increasing doses of EFPA in rats
Groups Urine volume (mL/100 g) Urinary volumetric excretion (%)
2 h 4 h 6 h 8 h 2 h 4 h 6 h 8 h
Control 0.14 ± 0.09 0.20 ± 0.07 0.50 ± 0.04 0.70 ± 0.05 2.70 ± 2.83 3.80 ± 1.10 8.76 ± 0.80 13.62 ± 0.92
EFPA (5 mg/kg) 0.84 ± 0.11* 1.49 ± 0.14* 1.73 ± 0.20* 2.09 ± 0.17* 16.61 ± 2.01* 29.40 ± 3.02* 34.20 ± 3.64* 41.20 ± 3.32*
EFPA (10 mg/kg) 1.14 ± 0.13* 1.82 ± 0.11* 2.21 ± 0.15* 2.80 ± 0.20* 22.92 ± 2.60* 36.50 ± 2.53* 44.20 ± 3.80* 55.94 ± 3.40*
EFPA (20 mg/kg) 1.67 ± 0.15* 2.06 ± 0.16* 2.34 ± 0.10* 2.86 ± 0.12* 33.30 ± 4.10* 41.23 ± 2.90* 46.80 ± 2.70* 57.10 ± 1.90*
EFPA (40 mg/kg) 2.02 ± 0.11* 2.34 ± 0.10* 2.51 ± 0.18* 3.09 ± 0.13* 40.60 ± 1.70* 47.12 ± 2.83* 50.53 ± 3.80* 60.20 ± 2.90*
EFPA (80 mg/kg) 2.33 ± 0.12* 2.60 ± 0.13* 2.92 ± 0.13* 3.16 ± 0.15* 46.61 ± 2.10* 51.90 ± 2.73* 58.41 ± 1.91* 63.34 ± 3.24*
The urine volumes expressed as mL/100 g were calculated based on body weight of rats and urinary volumetric excretion values are expressed as a percentage of
the initial hydric overload (50 mL/kg). Data are given as means ± SEM of 6 different experiments. Statistical analyses were assessed using two-way analysis of vari-
ance (ANOVA) followed by Bonferroni’s post- test. *p ˂ 0.001 versus control
Fig. 1 Evolution of the urinary volumetric excretion induced by
highest dose of EFPA (80 mg/kg) and Furosemide (5 mg/kg), in rats.
The urinary volumetric excretion values are expressed as a percentage
of the initial hydric overload (50 mL/kg). Data are given as means ±
SEM of 6 different experiments. Statistical analyses were assessed using
two-way analysis of variance (ANOVA) followed by Bonferroni’s post-
test. *p < 0.001 versus control, and #p < 0.05 versus EFPA
Fig. 2 Inhibitory effect of indomethacin on urinary volumetric
excretion induced by EFPA in rats. Rats were treated over 8 h period
with a single dose of either vehicle (control group), EFPA (10 mg/kg)
or EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h pretreatment)
administered i.p. Data are given as means ± SEM of 6 different
experiments. Statistical analyses were assessed using one-way analysis
of variance (ANOVA) followed by Bonferroni’s post- test *p < 0.05 versus
control, and #p < 0.05 versus EFPA
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present findings indicate that EFPA induced important
urinary excretion of sodium (43 mEq) in consistent with
previous observations showing that a preparation of the
whole plant of Phyllanthus amarus caused significant
urinary sodium excretion in hypertensive humans [12].
Furthermore, the EFPA-induced natriuresis was associ-
ated with urinary excretion of chlorine (97 mEq) without
promoting excretion of potassium. In addition, a leaf ex-
tract of Ficus exasperata (50 mg/kg, per os) also signifi-
cantly decreased the plasma sodium level without
promoting kaliuresis in rats [26].
Preliminary phytochemical analysis of EFPA revealed
the presence of alkaloids, polyphenols, terpenes and ste-
rols [14]. The diuretic effect of EFPA could be most
likely related to these secondary active metabolites. In-
deed, polyphenolic compounds, triterpenoids and sapo-
nins have been described to contribute to the diuretic
effect of several plant extracts including Musanga cecro-
pioides, Viscum angulatum, Hibiscus sabdariffa and
Nigella sativa [27–30].
Furosemide, a highly effective loop diuretic induced
considerable loss of water associated with an urinary ex-
cretion of sodium, chlorine and potassium. However,
previous reports have also indicated that Furosemide did
not affect significantly the efflux of potassium in normal
rats [31, 32]. Thus, the EFPA treatment seems to induce
a similar diuretic effect as that of Furosemide, without a
loss of potassium. The main mechanism associated with
loop diuretics is linked to inhibition of the co-transport
system Na+/K+/2Cl− of the ascending limb of the loop of
Henle [33]. Thus, EFPA could possibly act upon this part
of the nephron to exert an inhibition of sodium chloride
reabsorption and, hence, inducing a significant urinary
elimination of water. Moreover, the diuretic effect of
EFPA could also be related to other mechanisms such as
affecting prostaglandin E2 (PGE2) formation, which regu-
lates kidney function in the distal nephron by stimulat-
ing excretion of sodium via inhibition of vasopressin-
stimulated water and sodium absorption in the collect-
ing duct [34, 35]. In addition, PGE2 has been shown to
play a key role in reducing vascular tone, and, hence, in-
creasing renal blood flow leading to an increase of water
exchange and transmembrane electrolyte, and an in-
creased glomerular filtration rate [36, 37]. PGE2 is syn-
thesized by the cycloxygenase COX-1 and COX-2
located in the cortical zone of the renal tissue. Previous
studies have indicated that inhibition of COX-1 and
COX-2 with indomethacin resulted in retention of
Table 2 Inhibitory effect of indomethacin on urinary electrolyte excretion induced by EFPA in rats
Groups Urinary concentrations (mEq/L)
Na+ Cl− K+ Ca2+
Control 70.50 ± 6.05 81.20 ± 3.10 52.20 ± 2.01 1.80 ± 0.10
EFPA (10 mg/kg) 90.00 ± 4.70* 97.33 ± 2.90* 36.70 ± 1.63* 1.73 ± 0.10
EFPA (10 mg/kg) + Indomethacin (5 mg/kg) 43.50 ± 4.43*,# 96.70 ± 4.10* 61.00 ± 2.42*,# 3.10 ± 0.20
Rats were treated over a 24 h period with a single dose of vehicle (control group), EFPA (10 mg/kg) or EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h
pretreatment) administered i.p. Data are given as means ± SEM of 6 different experiments. Statistical analyses were assessed using two-way analysis of variance
(ANOVA) followed by Bonferroni’s post- test. *p < 0.05 versus control, and #p < 0.05 versus EFPA
Table 3 Inhibitory effect of indomethacin on plasma electrolyte level induced by EFPA in rats
Groups Plasma levels (mEq/L)
Na+ Cl− K+ Ca2+
Control 114.70 ± 5.51 104.33 ± 3.90 70.50 ± 2.90 5.40 ± 2.52
EFPA (10 mg/kg) 125.50 ± 4.00 102.00 ± 4.32 54.70 ± 2.80* 5.21 ± 2.60
EFPA (10 mg/kg) + Indomethacin (5 mg/kg) 119.33 ± 4.43 103.33 ± 3.41 50.83 ± 5.10* 5.13 ± 2.54
Rats were treated over a 24 h period with a single dose of either vehicle (control group), EFPA (10 mg/kg) or EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h
pretreatment) administered i.p. Data are given as means ± SEM of 6 different experiments. Statistical analyses were assessed using two-way analysis of variance
(ANOVA) followed by Bonferroni’s post- test. *p < 0.05 versus control, and #p < 0.05 versus EFPA
Table 4 Effects of EFPA (10 mg/kg) and EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h pretreatment) administered i.p. on plasma
levels of creatinine and urea
Groups Control EFPA (10 mg/kg) EFPA (10 mg/kg) + Indomethacin (5 mg/kg)
Creatinine (μmol/L) 94.28 ± 7.80 88.40 ± 4.56 110.47 ± 6.75#
Urea (mmol/L) 4.08 ± 0.38 3.29 ± 0.43 5.83 ± 0.58*, #
Data are given as means ± SEM of 6 different experiments. Statistical analyses were assessed using one-way analysis of variance (ANOVA) followed by Bonferroni’s post- test
*p < 0.05 versus control, and #p< 0.05 versus EFPA
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sodium and water associated with hypertension and
edema in rats [34]. The present study indicates that
treatment of rats with indomethacin significantly re-
duced the natriuretic and the diuretic responses of
EFPA. These findings suggest that the diuretic pro-
perties of Phyllanthus amarus can be partially attrib-
uted, at least in part, to the involvement of diuretic
prostaglandins. A similar mechanism has also been
involved in the diuretic effect of several extracts of
plant species used in traditional medicine such as
Selaginella nothohybrida, Selaginella lepidophylla and
Tropaeolum majus [31, 38].
The potassium-sparing effect of EFPA supposes also
an action on the distal convoluted tubule and/or cortical
collecting tube possibly by inhibiting the mineralocortic-
oid receptor, or with the exchanger Na+ / K+ by blocking
sodium channels at the luminal membrane, respectively
[25]. The present findings also indicate that Phyllanthus
amarus could stimulate kidney function without causing
an adverse effect on blood urea and creatinine [39].
Conclusion
The present findings indicate diuretic properties of an etha-
nolic fraction of Phyllanthus amarus aqueous extract asso-
ciated with significant urinary excretion of Na+ and water,
which involves diuretic prostaglandins, supporting its use
in traditional medicine as a potential remedy against hyper-
tension. The diuretic activity of the Phyllanthus amarus
extract might contribute to explain the hypotensive action
shown previously in normal rabbits [14]. Further studies
are needed to evaluate the effectiveness of EFPA in experi-
mental models of hypertension, and to identify the bio-
active compounds responsible for the diuretic properties.
Additional files
Additional file 1: Figure S1. Urinary volumetric excretion induced by
increasing doses of EFPA in rats. The urinary volumetric excretion values are
expressed as a percentage of the initial hydric overload (50 mL/kg). Data are
given as means ± SEM of 6 different experiments. Statistical analyses were
assessed using two-way analysis of variance (ANOVA) followed by Bonferro-
ni’s post- test. *p ˂ 0.001 versus control. (TIFF 216 kb)
Additional file 2: Figure S2. Inhibitory effect of indomethacin on
urinary electrolyte excretion induced by EFPA in rats. Rats were treated
over a 24 h period with a single dose of vehicle (control group), EFPA
(10 mg/kg) or EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h
pretreatment) administered i.p. Data are given as means ± SEM of 6
different experiments. Statistical analyses were assessed using two-way
analysis of variance (ANOVA) followed by Bonferroni’s post- test. *p < 0.05
versus control, and #p < 0.05 versus EFPA. (TIFF 140 kb)
Additional file 3: Figure S3. Inhibitory effect of indomethacin on
plasma electrolyte level induced by EFPA in rats. Rats were treated over a
24 h period with a single dose of either vehicle (control group), EFPA
(10 mg/kg) or EFPA (10 mg/kg) + indomethacin (5 mg/kg, 1 h
pretreatment) administered i.p. Data are given as means ± SEM of 6
different experiments. Statistical analyses were assessed using two-way
analysis of variance (ANOVA) followed by Bonferroni’s post- test. *p < 0.05
versus control, and #p < 0.05 versus EFPA. (TIFF 174 kb)
Abbreviations
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mEq: Milliequivalents; Na+: Sodium; SEM: Standard error mean; UVE: Urinary
volumetric excretion
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